Eli Lilly and Company will participate in the 44th Annual J.P. Morgan Healthcare Conference in January 2026.
The company plans to address previous supply chain challenges that caused revenue shortfalls for its popular GLP-1 products. Lilly will also outline its long-term growth strategy during the presentation.
This strategy focuses on scaling up manufacturing capabilities and disciplined execution. These efforts are designed to meet high product demand.
Lilly frames the appearance as an effort to shift the narrative from past supply constraints to future execution. The company seeks to reassure investors by demonstrating progress in expanding production and highlighting the breadth of its development pipeline. Initiatives presented will support sustained growth across the portfolio.